KIF23 is a potential biomarker of diffuse large B cell lymphoma

Abstract

Diffuse Large B Cell Lymphoma (DLBCL), the most common form of blood cancer. The genetic and clinical heterogeneity of DLBCL poses a major barrier to diagnosis and treatment. Hence, we aim to identify potential biomarkers for DLBCL.Differentially expressed genes were screened between DLBCL and the corresponding normal tissues. Kyoto Encyclopedia of Genes and Genomes and Gene oncology analyses were performed to obtain an insight into these differentially expressed genes. PPI network was constructed to identify hub genes. survival analysis was applied to evaluate the prognostic value of those hub genes. DNA methylation analysis was implemented to explore the epigenetic dysregulation of genes in DLBCL.In this study, Kinesin family member 23 (KIF23) showed higher expression in DLBCL and was identified as a risk factor in DLBCL. The immunohistochemistry experiment further confirmed this finding. Subsequently, the univariate and multivariate analysis indicated that KIF23 might be an independent adverse factor in DLBCL. Upregulation of KIF23 might be a risk factor for the overall survival of patients who received an R-CHOP regimen, in late-stage, whatever with or without extranodal sites. Higher expression of KIF23 also significantly reduced 3, 5, 10-year overall survival. Furthermore, functional enrichment analyses (Kyoto Encyclopedia of Genes and Genomes, Gene oncology, and Gene Set Enrichment Analysis) showed that KIF23 was mainly involved in cell cycle, nuclear division, PI3K/AKT/mTOR, TGF-beta, and Wnt/beta-catenin pathway in DLBCL. Finally, results of DNA methylation analysis indicated that hypomethylation in KIF23's promoter region might be the result of its higher expression in DLBCL.The findings of this study suggested that KIF23 is a potential biomarker for the diagnosis and prognosis of DLBCL. However, further studies were needed to validate these findings.

Identification and validation of a platelet-related signature for predicting survival and drug sensitivity in multiple myeloma

“…However, the signaling pathways associated with it in relation to cancer development are currently unclear and need to be further investigated. KIF23 plays a key role in cell proliferation, metabolism, differentiation, metastasis and survival through the activation of PI3K/AKT/mTOR and Wnt/β/Linker protein signaling pathway ( Huang et al, 2022 ; Jin et al, 2022 ), and has been demonstrated in cancers such as gastric cancer and diffuse large B-cell lymphoma ( Gong et al, 2022 ; Bai and Liu, 2023 ). The role of other negative genes in tumors still needs to be further discussed and explored.…”

Bioinformatics analysis of the pathogenic link between Epstein-Barr virus infection, systemic lupus erythematosus and diffuse large B cell lymphoma

“…KIF23, a kinesin 6 family member that is found at the interzone of mitotic spindles, is essential for cytokinesis 38 . KIF23 expression is increased in DLBCL and is a risk factor for this disease 39 . NEK2, a member of NIMA-related kinase family that regulates cell cycle, is up-regulated in a variety of malignancies, including DLBCL 40 , 41 .…”

The metabolic role of lactate dehydrogenase in the growth of diffuse large B cell lymphoma

“…Inhibition of LDHA can limit the energy supply in cancer cells, thereby reducing metastasis and invasion of cancer cells 17 . Many studies have suggested that LDHA is a prognostic factor and a potential target for treatment in DLBCL [18][19][20][21][22] . Metabolism-related gene LDHA was highly expressed in malignant B cells in DLBCL tissue which was clustered using scRNA-seq 23 .…”